A radiation-sensitive resin composition includes a polymer including a phenolic hydroxyl group, a compound represented by formula (1-1) or formula (1-2), and a compound represented by formula (2). In the formula (1-1), a sum of a, b, and c is no less than 1; at least one of R.sup.1, R.sup.2, and R.sup.3 represents a fluorine atom or the like; and R.sup.4 and R.sup.5 each independently represent a hydrogen atom, a fluorine atom, or the like. In the formula (1-2), in a case in which d is 1, R.sup.6 represents a fluorine atom or the like, and in a case in which d is no less than 2, at least one of the plurality of R.sup.6s represents a fluorine atom or the like; and R.sup.8 represents a single bond or a divalent organic group having 1 to 20 carbon atoms.

##STR00001##

A radiation-sensitive resin composition includes a polymer including a phenolic hydroxyl group, a compound represented by formula (1-1) or formula (1-2), and a compound represented by formula (2). In the formula (1-1), a sum of a, b, and c is no less than 1; at least one of R.sup.1, R.sup.2, and R.sup.3 represents a fluorine atom or the like; and R.sup.4 and R.sup.5 each independently represent a hydrogen atom, a fluorine atom, or the like. In the formula (1-2), in a case in which d is 1, R.sup.6 represents a fluorine atom or the like, and in a case in which d is no less than 2, at least one of the plurality of R.sup.6s represents a fluorine atom or the like; and R.sup.8 represents a single bond or a divalent organic group having 1 to 20 carbon atoms.

##STR00001##

The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

The present invention relates to compounds of formula (I): including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

The invention relates to fluorene derivatives and electronic devices, particularly organic electroluminescent devices in which said compounds are used, particularly as a matrix material for phosphorescent emitters.

The present invention provides a novel group of active peptide compounds based on the psychoactive safrylamine compounds MDMA, MDA, MMDA-2, and MDAI. Thereby, the invention provides for improved pharmacokinetic properties during uptake of the safrylamines, as well as reduced side effects resulting from the metabolites thus formed. Due to the affinity of the novel safrylamine derivatives for the 5-HT2a-receptor, the invention can find use in numerous forms of therapy, such as against depression or posttraumatic stress disorder (PTSD).

The present invention provides a novel group of active peptide compounds based on the psychoactive safrylamine compounds MDMA, MDA, MMDA-2, and MDAI. Thereby, the invention provides for improved pharmacokinetic properties during uptake of the safrylamines, as well as reduced side effects resulting from the metabolites thus formed. Due to the affinity of the novel safrylamine derivatives for the 5-HT2a-receptor, the invention can find use in numerous forms of therapy, such as against depression or posttraumatic stress disorder (PTSD).

The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

Described herein is a compound of formula (I)

##STR00001##

in the form of any one of its stereoisomers or as a mixture thereof, and wherein R.sup.1 represents a hydrogen atom, a C.sub.1-3 alkyl group or C.sub.2-3 alkenyl group; X represents an oxygen atom when R.sup.2 represents a C.sub.1-4 alkyl group or C.sub.2-4 alkenyl group or X represents a CH2-O group when R.sup.2 represents a C.sub.2-4 alkenyl group or a MeC═O group. The use as a perfuming ingredient of this compound and this compound as part of a perfuming composition or of a perfuming consumer product are also described.